LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

Search

Simulations Plus Inc

Cerrado

SectorSanidad

11.55 0.35

Resumen

Variación precio

24h

Actual

Mínimo

11.3

Máximo

11.72

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+64.22% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.52%

Próximas Ganancias

2 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-127M

241M

Apertura anterior

11.2

Cierre anterior

11.55

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

167 / 350 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 mar 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Infosys Agrees to Acquire Stratus

25 mar 2026, 23:58 UTC

Ganancias

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25 mar 2026, 23:58 UTC

Ganancias

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25 mar 2026, 23:57 UTC

Ganancias

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25 mar 2026, 23:57 UTC

Ganancias

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25 mar 2026, 23:56 UTC

Ganancias

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25 mar 2026, 23:56 UTC

Ganancias

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25 mar 2026, 23:41 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25 mar 2026, 23:41 UTC

Ganancias

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25 mar 2026, 23:34 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Declines on Possible Technical Correction -- Market Talk

25 mar 2026, 22:08 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 mar 2026, 22:08 UTC

Charlas de Mercado

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25 mar 2026, 21:58 UTC

Charlas de Mercado

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25 mar 2026, 21:37 UTC

Charlas de Mercado

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25 mar 2026, 21:14 UTC

Adquisiciones, fusiones, absorciones

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25 mar 2026, 21:13 UTC

Adquisiciones, fusiones, absorciones

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25 mar 2026, 21:12 UTC

Adquisiciones, fusiones, absorciones

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

25 mar 2026, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

25 mar 2026, 20:33 UTC

Adquisiciones, fusiones, absorciones

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25 mar 2026, 20:31 UTC

Ganancias

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

64.22% repunte

Estimación a 12 Meses

Media 19 USD  64.22%

Máximo 19 USD

Mínimo 19 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

167 / 350 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat